← Eichor
Condition: Serous Ovarian Tumor Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Serous Ovarian Tumor

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
Phase 3 · 106 location(s) · Verastem, Inc. · NCT06072781Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer
Phase 1 · 27 location(s) · National Cancer Institute (NCI) · NCT04633239Chemotherapy Combined With Propranolol Hydrochloride as Neoadjuvant Therapy for Advanced High-grade Serous Ovarian Cance
Phase 2 · 1 location(s) · Bai-Rong Xia · NCT07125391Trial of THEO-260 (Administered Via Intraperitoneal Route) in Ovarian Cancer Patients
Phase 1 · 1 location(s) · Theolytics Limited · NCT07211659MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)
Phase 3 · 53 location(s) · Swiss GO Trial Group · NCT04111978Niraparib Rechallenge After Surgery in Ovarian Cancer Patients With Oligometastatic Progression
Phase 2 · 14 location(s) · MedSIR · NCT06180356This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Tor
Phase 1 · 3 location(s) · Zumutor Biologics Inc. · NCT06451497Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Beva
Phase 3 · 32 location(s) · Genelux Corporation · NCT05281471Abemaciclib and Letrozole in Patients With Estrogen Receptor-positive Rare Ovarian Cancer
Phase 2 · 12 location(s) · Universitaire Ziekenhuizen KU Leuven · NCT05872204Early Diagnosis of High-grade Serous Epithelial Ovarian Cancer Through the Analysis of DNA Derived From Pap Test Smear.
NA · 1 location(s) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · NCT07556562A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)
Phase 1/Phase 2 · 29 location(s) · Merck Sharp & Dohme LLC · NCT06843447Letrozole for Estrogen/Progesterone Receptor Positive Low-grade Serous Epithelial Ovarian Cancer (LEPRE Trial)
Phase 3 · 19 location(s) · Ente Ospedaliero Ospedali Galliera · NCT05601700Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16)
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07480954Study of CryptiVax-1001 in Maintenance Setting for Advanced Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase 1 · 10 location(s) · Epitopea Ltd · NCT07665515Multi-layer Data to Improve Diagnosis, Predict Therapy Resistance and Suggest Targeted Therapies in HGSOC
NA · 1 location(s) · Turku University Hospital · NCT04846933Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring
Phase 2 · 3 location(s) · Centre Oscar Lambret · NCT05500391A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
Phase 1/Phase 2 · 14 location(s) · Volastra Therapeutics, Inc. · NCT05902988Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Phase 1/Phase 2 · 66 location(s) · Genmab · NCT05579366Peritoneal Surface Malignancies - Characterization, Models and Treatment Strategies
Phase N/A · 1 location(s) · Oslo University Hospital · NCT02073500A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors
Phase 1 · 17 location(s) · NextCure, Inc. · NCT06792552Personalized Patient Derived Xenograft (pPDX) Modeling to Test Drug Response in Matching Host
Phase N/A · 1 location(s) · University Health Network, Toronto · NCT02732860First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Incl
Phase 1 · 6 location(s) · Accent Therapeutics · NCT06799065Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer
Phase 1/Phase 2 · 16 location(s) · Scancell Ltd · NCT05329532Ventral Hernias Following Cytoreductive Surgery : Incidence, Risk Factors and Surgical Management.
Phase N/A · 1 location(s) · Jules Bordet Institute · NCT07451483Data Collection for Patients With Low Grade Ovarian or Peritoneal Tumors
Phase N/A · 1 location(s) · M.D. Anderson Cancer Center · NCT00488878Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Re
Phase 2 · 2 location(s) · Roswell Park Cancer Institute · NCT05231122Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal
Phase 3 · 19 location(s) · M.D. Anderson Cancer Center · NCT04575935Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of
EARLY_Phase 1 · 1 location(s) · Ohio State University Comprehensive Cancer Center · NCT05415709A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary
Phase 2 · 92 location(s) · K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis P · NCT05128825Adaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive High Grade Serous or High Grade En
Phase 2 · 1 location(s) · University College, London · NCT05080556
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.